CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 75 enrolled
Drug / intervention
afliberceptdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00407654
NCT00407654Phase 2Completed
CompareCT.gov

Phase II Trial of VEGF Trap in Patients With Previously Treated Metastatic Colorectal Cancer

National Cancer Institute (NCI)·interventional·Posted Dec 5, 2006·Updated Mar 4, 2024

In Brief

A Phase 2 clinical trial evaluating aflibercept for Recurrent Colon Cancer and 3 related conditions. Completed, enrolled 75 participants across 1 site.

Detailed Summary

This phase II trial is studying how well VEGF Trap works in treating patients with previously treated metastatic colorectal cancer. VEGF Trap may stop the growth of colorectal cancer by blocking blood flow to the tumor.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRecurrent Colon Cancer, Recurrent Rectal Cancer, Stage IV Colon Cancer, Stage IV Rectal Cancer
CountriesCanada
Collaborators--

Timeline

Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedDec 5, 2006
Enrollment StartOct 1, 2006
Primary CompletionSep 1, 2012
TodayJul 2, 2026
Enrollment to primary: 5.9 yearsPosted 19.6 years ago

Interventions

afliberceptdrug

Given intravenously